TP10

DRUG2 trials

Sponsors

Avant Immunotherapeutics, University of Iowa

Conditions

Aortic Valve InsufficiencyCoronary ArteriosclerosisDense Deposit DiseaseMitral Valve InsufficiencyMyocardial Ischemia

Phase 1

TP10 Use in Patients With C3 Glomerulopathy (C3G)

WithdrawnNCT02302755

University of IowaDense Deposit Disease

Start: 2014-11-30End: 2016-10-31Updated: 2016-10-27

Phase 2

Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery

CompletedNCT00082121

Avant ImmunotherapeuticsAortic Valve Insufficiency, Coronary Arteriosclerosis, Mitral Valve Insufficiency +1

Start: 2004-04-30End: 2005-12-31Target: 300Updated: 2007-07-20